Distinguished Professor, Department of Pediatrics
To see if Randi Jenssen Hagerman is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
Pediatric Child Development & Behavior
I believe that multi-modality interventions can be synergistic and targeted treatments can be very helpful for many disorders.
Dr. Hagerman's main areas of research are targeted treatment trials in Fragile X Syndrome (FXS), Rett Syndrome, Fragile X-associated Tremor/Ataxia Syndrome (FXTAS), and Autism Spectrum Disorder (ASD). Her clinical patients include: FXS, FXTAS, ASD, and other neurodevelopmental disorders.
Randi Hagerman, M.D., FAAP, is a Distinguished Professor of Pediatrics at the University of California Davis Medical Center and Director of the Fragile X Research and Treatment Center at the MIND Institute and holds an Endowed Chair in Fragile X Research. Dr. Hagerman is a developmental and behavioral pediatrician and has studied patients with fragile X syndrome (FXS), autism (ASD), and other neurodevelopmental disorders. She has carried out numerous targeted treatment studies in FXS and autism. She and her husband and team have published extensively regarding fragile X premutation disorders including the first description of FXTAS in 2001. She co-founded the National Fragile X Foundation in 1984 and has been involved in targeted treatments for fragile X syndrome, autism, and FXTAS for several years. Dr Hagerman has written over 400 peer-reviewed articles and several books on fragile X and autism. Her most recent books are R. Hagerman and R. Hendren (eds) (2014) Treatment of Neurodevelopmental Disorders: Targeting Neurobiological Mechanisms published by Oxford University Press and, E. Hollander, R. Hagerman and D. Fein (eds) (2018) Autism Spectrum Disorders, American Psychiatric Association Publishing; in 2020, two books including: 2nd Edition of Textbook of Autism Spectrum Disorders, E. Hollander, R. Hagerman and C. Ferretti (eds), American Psychiatric Publishing Inc. (APPI); and, Fragile X Syndrome and the Premutation: New Developments and Treatments, Hagerman RJ and Hagerman PJ, (eds), Mac Keith Press.
Child Development and Behavior
B.S., UC Davis, Davis CA 1971
M.D., F.A.A.P., Stanford University School of Medicine, Palo Alto CA 1975
Stanford University School of Medicine, Palo Alto CA 1975-1976
Stanford University School of Medicine, Palo Alto CA 1976-1977
UC San Diego, La Jolla CA 1979-1980
UC San Diego, La Jolla CA 1978-1980
UC Davis Endowed Chair in Fragile X Research, 2005 to present,
Emil M. Mrak International Award, Cal Aggie Alumni Association, 2017
International Sisley-Jerome Lejeune Award, Strasbourg, 2014
C. Anderson Aldrich Award for Outstanding Career Achievement, American Academy of Pediatrics, SODBP, 2014
Distinguished Scholarly Public Service Award, UC Davis, Office of the Academic Senate, 2014
The Pearl H. Rieger Award, Rush Neurobehavioral Center, 2012
Sewall Rehabilitation Center: Distinguished Service Award, 2011
Distinguished Alumni Award, UC Davis, College of Biological Sciences, 2011
Distinguished Alumni Award, UC Davis College of Biological Sciences, 2011,
Board of Directors, National Fragile X Foundation, 1997 to 2010,
Princeton Lecture Series Fellowship, 2010,
Review of Application on FXTAS for Veteran’s Administration, 2012
FAS Task Force of Santa Clara Advisory Board, 2003, 2004, 2005, 2006, 2007, 2008, 2009
Advisory Board of the Fragile X Association of Northern California, 1996 to 2009,
Scientific Council of L'Association Mosaiques (Paris), 1997 to 2009,
Advisory Committee for the VA/UCD General Clinical Research Center, 2003, 2004, 2005, 2006, 2007, 2008, 2009
Advisory Board of the Los Angeles Fragile X Association, 1997 to 2009,
Lifetime Achievement Award, National Fragile X Foundation, 2008,
UC Davis Distinguished Scholarly Public Service Award, 2005,
UC Davis Dean’s Excellence in Mentoring Award, 2005,
Namesake (with Paul Hagerman), Hagerman Award for Research in FXTAS, International Association for the Study of Intellectual Deficiency, 2004,
IASSID Distinguished Achievement Award for Scientific Literature, 2004,
NFXF named the Hagerman Award for Research in FXTAS after the research of Randi and Paul Hagerman, 2004
SOM Faculty Research Award, UC Davis, 2004
Distinguished Visiting Professor, La Trobe University, Melbourne, Australia, 2004
The Rhoda G. & Bernard G. Sarnat Endowed Lecturer, Cedars Sinai Medical Center, Los Angeles, 2004
The 2003 Andrew J. Kirch Visiting Scholar at U of Rochester, 2003
Director of Research: Colorado UAP, 1997, 1998, 1999, 2000
Associate Editor of the American Journal on Mental Retardation, 1996, 1997, 1998
Distinguished Visiting Fellow, LaTrobe University, Melbourne, Australia, 1995
Bonfils-Stanton Foundation Award for Science including Medicine, 1993,
Jerrett Cole Award, National Fragile X Foundation, 1992,
North Metro Community Services Award, 1985
Community Service Award from Passages, One of 14 "Women Who Care 1985", 1985
Innovative Research Award from AAMD American Association of Mental Deficiency Colorado Chapter, 1984
Outstanding Intern of the Year Award: Stanford Medical School, Pediatrics Department, 1976
Valedictorian of graduating class; graduation speaker (U.C. Davis; College of Letters and Science), 1971
McKinney WS, Bartolotti J, Khemani P, Wang JY, Hagerman RJ, Mosconi MW. Cerebellar-cortical function and connectivity during sensorimotor behavior in aging FMR1 gene premutation carriers. Neuroimage Clin. 2020;27:102332. doi:10.1016/j.nicl.2020.102332. Epub 2020 Jul 2. PMID:32711390.
Berry-Kravis E, Horrigan JP, Tartaglia N, Hagerman R, Kolevzon A, Erickson CA, Hatti S, Snape M, Yaroshinsky A, Stoms G; FXS-001 Investigators, Glass L, Jones NE. A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Fragile X Syndrome. Pediatr Neurol. 2020 Sep;110:30-41. doi:10.1016/j.pediatrneurol.2020.04.019. Epub 2020 May 23. PMID:32660869.
Schneider A, Winarni TI, Cabal-Herrera AM, Bacalman S, Gane L, Hagerman P, Tassone F, Hagerman R. Elevated FMR1-mRNA and lowered FMRP - A double-hit mechanism for psychiatric features in men with FMR1 premutations. Transl Psychiatry. 2020 Jun 23;10(1):205. doi:10.1038/s41398-020-00863-w. PMID:32576818.
Cabal-Herrera AM, Tassanakijpanich N, Salcedo-Arellano MJ, Hagerman RJ. Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS): Pathophysiology and Clinical Implications. Int J Mol Sci. 2020 Jun 20;21(12):4391. doi:10.3390/ijms21124391. PMID:32575683.
Jasoliya M, Bowling H, Petrasic IC, Durbin-Johnson B, Klann E, Bhattacharya A, Hagerman R, Tassone F. Blood-Based Biomarkers Predictive of Metformin Target Engagement in Fragile X Syndrome. Brain Sci. 2020 Jun 10;10(6):361. doi:10.3390/brainsci10060361. PMID:32531912.
Cabal-Herrera AM, Saldarriaga-Gil W, Salcedo-Arellano MJ, Hagerman RJ. Fragile X associated neuropsychiatric disorders in a male without FXTAS. Intractable Rare Dis Res. 2020 May;9(2):113-118. doi:10.5582/irdr.2020.01028. PMID:32494560.
Salcedo-Arellano MJ, Cabal-Herrera AM, Tassanakijpanich N, McLennan YA, Hagerman RJ. Ataxia as the Major Manifestation of Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS): Case Series. Biomedicines. 2020 May 25;8(5):136. doi:10.3390/biomedicines8050136. PMID:32466255.
Salcedo-Arellano MJ, Wolf-Ochoa MW, Hong T, Amina S, Tassone F, Lechpammer M, Hagerman R, Martínez-Cerdeño V. Parkinsonism Versus Concomitant Parkinson's Disease in Fragile X-Associated Tremor/Ataxia Syndrome. Mov Disord Clin Pract. 2020 Apr 9;7(4):413-418. doi:10.1002/mdc3.12942. eCollection 2020 May. PMID:32373658.
Alolaby RR, Jiraanont P, Durbin-Johnson B, Jasoliya M, Tang HT, Hagerman R, Tassone F. Molecular Biomarkers Predictive of Sertraline Treatment Response in Young Children With Autism Spectrum Disorder. Front Genet. 2020 Apr 15;11:308. doi:10.3389/fgene.2020.00308. eCollection 2020. PMID:32346385.
Casanova MF, Casanova EL, Frye RE, Baeza-Velasco C, LaSalle JM, Hagerman RJ, Scherer SW, Natowicz MR. Editorial: Secondary vs. Idiopathic Autism. Front Psychiatry. 2020 Apr 14;11:297. doi:10.3389/fpsyt.2020.00297. eCollection 2020. PMID:32346372.